Results 41 to 50 of about 634 (79)

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon

Pharmacology Research &Perspectives, Volume 13, Issue 1, February 2025.
ABSTRACT Dersimelagon is a novel investigational orally administered selective agonist of the melanocortin‐1 receptor. The drug–drug interaction (DDI) potential of dersimelagon was investigated in both nonclinical (in vitro) and clinical studies. The in vitro inhibition of CYP/UGT isoforms and efflux/uptake transporters by dersimelagon was assessed ...
Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Minoru Tsuda, Renli Teng   +4 more
wiley   +1 more source

Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)

British Journal of Clinical Pharmacology, Volume 91, Issue 2, Page 451-463, February 2025.
Abstract Aims Dersimelagon is a novel, investigational, orally administered, selective agonist of the melanocortin‐1 receptor that has demonstrated efficacy at increasing symptom‐free light exposure and an acceptable safety profile in patients with protoporphyria. A phase 1 drug–drug interaction (DDI) study demonstrated that dersimelagon 300 mg has the
Akihito Ogasawara, Koki Kojima, Yukiko Murata, Hidetoshi Shimizu   +3 more
wiley   +1 more source

Advances in the management of erythropoietic protoporphyria – role of afamelanotide

The Application of Clinical Genetics, 2016
Ashley M Lane,1 Jerome T McKay,2 Herbert L Bonkovsky1 1Department of Internal Medicine, Section on Gastroenterology; 2Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC, USAAbstract ...
Lane AM, McKay JT, Bonkovsky HL
doaj  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Three‐generation female cohort with macrocytic anemia and iron overload

American Journal of Hematology, Volume 100, Issue 1, Page 133-138, January 2025.
Alexander A. Boucher, Vanessa J. Dayton, Annaliisa R. Pratt, Nicolas N. Nassar, Yasmin Elgammal, Theodosia A. Kalfa   +5 more
wiley   +1 more source

Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis. [PDF]

J Manag Care Spec Pharm
DerSarkissian M, Norregaard C, Romdhani H, Muthukumar A, Bobbili P, Chin M, Liu W, Trinh L.   +7 more
europepmc   +1 more source

Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release. [PDF]

Biochemistry, 2015
Fratz EJ, Clayton J, Hunter GA, Ducamp S, Breydo L, Uversky VN, Deybach JC, Gouya L, Puy H, Ferreira GC.   +9 more
europepmc   +1 more source

A Severe Reaction After Phototherapy in a Neonate With X-Linked Protoporphyria. [PDF]

Pediatrics
Sandgren JA, Tung ML, Berrebi KG, Saade DN, Bermick JR, Lee SS, Stanford AH.   +6 more
europepmc   +1 more source

Updates to gene-disease classifications and inheritance patterns for porphyrias. [PDF]

Mol Genet Metab
Reeves EB, Hankey W, Clair PS, Goldstein JL, Wilke MVMB, Feigenbaum A, Hung C, Spector E, Craigen WJ.   +8 more
europepmc   +1 more source